B+
Bull case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
AVTX
Avalo TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+45.9
Score
AI commentary
This remains a cautious monitoring setup rather than a high-conviction bullish thesis. Primary sources now clearly support the two key positives: Q2 2026 LOTUS timing and runway into 2028 [#10-K-2026-03-23]. But the deterministic prior is still near-neutral/slightly negative, catalyst density is only moderate, and almost all upside depends on a single readout. Recent conference/news flow points to investor focus on the same AVTX-009 Phase 2 window [#SERP-2][#SERP-3], which reinforces that the stock is likely to trade as a binary event vehicle until data.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventRunway confirmation reduces near-term dilution pressure ahead of dataHigh impact
The 10-K reported $98.3 million of cash, cash equivalents and short-term investments at December 31, 2025 and said current resources are expected to fund operations into 2028, which should keep near-term financing pressure lower as AVTX approaches LOTUS data [#10-K-2026-03-23].
2026-06-30catalystPhase 2 LOTUS topline data in Q2 2026High impact
Avalo’s 10-K says abdakibart (AVTX-009) is the lead asset, LOTUS enrollment was completed in October 2025, and management is preparing for a topline readout in the second quarter of 2026; this is the main value-setting catalyst for the stock [#10-K-2026-03-23].
2026-09-30eventPost-readout Phase 3 decision could surface milestone and capital implicationsHigh impact
Avalo said it is planning for Phase 3 trial(s), and the 10-K also notes a $15 million AlmataBio development milestone becomes due upon first patient dosed in a Phase 3 trial, payable in cash or stock at the holders’ election; a positive LOTUS outcome could therefore quickly shift debate to pivotal-trial design and funding terms [#10-K-2026-03-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology